欧阳亮，四川大学生物治疗全国重点实验室研究员，博士生导师。长期聚焦人类重大疾病开展创新药物研究，围绕肿瘤、神经退行性疾病及心血管等重大疾病的临床未满足需求，以临床价值为核心导向，系统构建“疾病调控网络解析-成药靶标识别-创新药物发现”一体化技术体系，开展新靶标、新机制挖掘与First-in-class创新药物创制研究，致力于通过创新药物研发解决人类重大疾病临床治疗瓶颈，推动研究成果向临床应用转化。近五年以通讯作者在Proc Natl Acad Sci USA、Angew Chem Int Ed、ACS Cent Sci、Acta Pharm Sin B、Signal Transduct Target Ther、J Med Chem等权威期刊发表论文66篇，其中ESI高被引论文3篇，研究成果被Nat Rev Drug Discov等期刊他引7511次，H指数47；申请发明专利21项，授权8项；主持国家级人才基金、重点研发计划等国家级项目8项，牵头四川省“原创小分子药物”科技创新群体等省部级项目6项。荣获中国施维雅青年药物化学奖、四川省学术和技术带头人、“天府万人计划”天府科技菁英、医科院医学健康长寿青年奖掖、中国产学研合作创新奖等荣誉。
现任四川省药理学会理事，四川省药理学会肿瘤药理专委会、四川省药物化学专委会委员，中国微循环学会微循环药物研究专委会常务委员以及中国药学会药物化学专委会青年委员；担任《药学学报》、Acta Pharm Sin B 青年编委，Journal of Medicinal Chemistry、Signal Transduction and Targeted Therapy 编委。
代表性科研项目：
1. 靶向自噬启动因子ULK1磷酸化修饰的化学干预及对帕金森病的潜在治疗研究, 22577086, 国家自然科学基金面上项目, 2026-01-01 至 2029-12-31, 主持
2. 靶向VEGFR3高选择性抑制剂设计合成，结构优化和抗三阴性乳腺癌淋巴转移作用机制研究, 82273770, 国家自然科学基金面上项目, 2023-01-01 至 2026-12-31, 主持
3. 药物化学, 81922064, 国家自然科学基金优秀青年基金，2020-01至2022-12, 主持.
4. 靶向BRD4-AMPK互作小分子化合物设计合成, 结构优化和诱导三阴性乳腺癌自噬性细胞死亡分子机制研究, 81874290, 国家自然科学基金面上项目, 2019-01至2022-12, 主持.
5. 基于调控线粒体功能的靶向SIRT3小分子化合物设计合成, 结构优化和治疗帕金森病作用机制研究, 81673290, 国家自然科学基金面上项目, 2017-01至2020-12,主持.
代表性论著：
1. Wu Y, Feng G, Shuai W, Yang X, Pan X, Zhu C, Wang A, Sun Q, Wang G*, Ouyang L*. Identification of a Selective YTHDF1 Inhibitor Targeting the m6A Recognition Domain for Breast Cancer. Angew Chem Int Ed Engl. 2025, 64，e202509316.
2. Sun Q, Tian X, Tan L, Deng Y, Liu S, Xiong Y, Feng Y, Wang Y, Zhang L, Zhu J, Xiao H, Shao Z*, Guo Y*, Yan W*, Li T*, Ouyang L*. Multiscale biased chemical space remodeling for developing APLNR agonists with anti-HFpEF efficacy. Proc Natl Acad Sci U S A. 2025, 122, e2423432122.
3. Zhang D, Zhang J, Wu C, Xiao Y, Ji L, Hu J, Ding J, Li T, Zhang Y*, Ouyang L*. Unraveling Small Molecule-Mediated Sirtuin 3 Activation at a Distinct Binding Site for Cardioprotective Therapies. ACS Cent Sci. 2025, 11, 704-718.
4. Shuai W, Yang P, Xiao H, Zhu Y, Bu F, Wang A, Sun Q, Wang G*, Ouyang L*. Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases. Angew Chem Int Ed Engl. 2024, 63, e202411037.
5. Li Y, Fu S, Yang J, Tang W, Zhang J*, Mao W*, Ouyang L*. Acrylamide Bioisosterism: Alkenyl Aromatic Heterocycles as Reactivity-Tunable Warheads for Covalent BTK Inhibitors. J Med Chem. 2026, 69, 5828-5850
6. Ouyang L*. First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance. J Med Chem. 2026, 69, 5166-5168
7. Ouyang L*. A transformer-based strategy to develop RP20 as a potent RIPK2 inhibitor for acetaminophen-induced acute liver injury. Acta Pharm Sin B. 2025, 15, 3831-3832.
8. Xiao H, Wang A, Shuai W, Qian Y, Wu C, Wang X, Yang P, Sun Q, Wang G*, Ouyang L*, Sun Q*. A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy. Signal Transduct Target Ther. 2025, 10, 70.
9. Yu B, Ouyang L*. Journal of Medicinal Chemistry Collection: Drug Discovery in China. J Med Chem. 2024, 67, 14700-14701.
10. Wang A, Shuai W, Wu C, Pei J, Yang P, Wang X, Li S, Liu J, Wang Y*, Wang G*, Ouyang L*. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFRL858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. J Med Chem. 2024 Feb 22;67(4):2777-2801.
11. Shuai W, Xiao H, Yang P, Zhang Y, Bu F, Wu Y, Sun Q*, Wang G*, Ouyang L*. Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors. J Med Chem. 2024, 67, 6425-6455.
12. Wang G, Wu Y, Wu C, Shuai W, Jiang T, Wang A, Bu F, Sun Q*, Ouyang L*. Rational design and crystallographic analysis of novel isoform-selective TRKA inhibitors for cancer therapy. Acta Pharm Sin B. 2023, 13, 440-443.
13. Shuai W, Bu F, Zhu Y, Wu Y, Xiao H, Pan X, Zhang J, Sun Q, Wang G*, Ouyang L*. Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2023, 66, 1273-1300.
14. Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J*, Ouyang L*. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy. J Med Chem. 2022. 65: 6803-6825.
欧阳亮，孙秋. 自噬与药物发现. 北京：科学出版社, 2024. 8.
研究生部公众号
川公网安备51010702002012